PT-141 (Bremelanotide, MW 1025.16 g/mol, CAS 189691-06-3) is a synthetic cyclic heptapeptide melanocortin receptor agonist with selective binding activity at MC3R and MC4R receptor subtypes. Its receptor selectivity profile distinguishes it from MT-2 in comparative melanocortin receptor pharmacology research panels.

MC3R and MC4R Receptor Binding Assays

Competitive radioligand binding assays using [125I]-NDP-alpha-MSH in MC3R and MC4R-expressing HEK293 membrane preparations characterise PT-141 binding affinity (Ki values) at each receptor subtype. Saturation binding experiments establish receptor density (Bmax) and equilibrium dissociation constants (Kd) in recombinant cell membrane systems. Competition binding curves generated with PT-141 concentrations ranging from 10^-11 to 10^-5 M demonstrate concentration-dependent displacement of radiolabeled ligand from both receptor subtypes.

Receptor Subtype Selectivity Profiling

Cross-reactivity screening across melanocortin receptor panel (MC1R through MC5R) reveals PT-141's preferential binding to MC3R and MC4R subtypes compared to other melanocortin family members. Binding affinity ratios calculated from IC50 determinations quantify selectivity indices between receptor subtypes in standardised membrane binding protocols.

cAMP Signalling Pathway Activation

G-Protein Coupled Receptor Signalling

MC3R and MC4R couple to Gαs proteins, initiating adenylyl cyclase activation and subsequent cAMP accumulation in transfected cell models. PT-141 demonstrates concentration-dependent cAMP elevation in CHO-K1 or HEK293 cells stably expressing recombinant MC3R or MC4R receptors. Real-time cAMP measurements using fluorescence polarisation immunoassays or luminescent detection systems quantify PT-141 potency (EC50 values) and maximal response (Emax) parameters.

Downstream Effector Analysis

Protein kinase A (PKA) activation downstream of cAMP elevation triggers CREB phosphorylation at serine-133 residues. Western blot analysis of phospho-CREB levels in PT-141-treated cells confirms functional receptor-effector coupling. Time-course experiments reveal peak CREB phosphorylation occurring 15-30 minutes post-treatment in MC3R/MC4R expressing cell models.

Comparative Pharmacological Characterisation

Structure-Activity Relationships

PT-141's cyclic peptide structure incorporates D-amino acid substitutions that enhance metabolic stability compared to linear melanocortin peptides. Comparative binding studies with α-MSH, β-MSH, and synthetic analogues establish structure-activity relationships within the melanocortin receptor family. Alanine scanning mutagenesis of MC3R and MC4R identifies critical residues for PT-141 binding and activation.

Receptor Desensitisation Studies

Prolonged PT-141 exposure induces receptor desensitisation through β-arrestin recruitment and receptor internalisation pathways. Confocal microscopy tracking fluorescently-labeled receptors demonstrates time-dependent receptor trafficking from plasma membrane to endosomal compartments. Recovery of cAMP responsiveness following ligand washout indicates receptor recycling kinetics in cultured cell systems.

Enzyme Kinetics and Binding Dynamics

Association and Dissociation Kinetics

Kinetic binding experiments measure PT-141 association (kon) and dissociation (koff) rate constants at MC3R and MC4R receptors. Real-time binding measurements using surface plasmon resonance or biolayer interferometry provide kinetic parameters for receptor-ligand interactions. Residence time calculations (1/koff) indicate duration of receptor occupancy in cell-free binding systems.

Allosteric Modulation Studies

Investigation of positive and negative allosteric modulators reveals cooperative binding effects at MC3R and MC4R receptors. Radioligand binding assays in presence of allosteric compounds demonstrate altered PT-141 binding affinity and cooperativity factors. Functional assays assess whether allosteric modulators influence PT-141 potency or efficacy in cAMP accumulation endpoints.

Cell Model Applications

Receptor Expression Systems

Stable transfection of MC3R or MC4R into parental cell lines creates reproducible expression systems for PT-141 pharmacology research. Quantitative PCR and receptor binding assays confirm consistent receptor expression levels across passages. Inducible expression systems using tetracycline-responsive promoters allow controlled receptor density manipulation in pharmacological studies.

Assay Development and Validation

High-throughput screening assays utilising 384-well plate formats enable large-scale PT-141 pharmacology screens. Assay validation parameters include Z-factor calculations, coefficient of variation determinations, and signal-to-background ratios for binding and functional endpoints. Quality control measures ensure reproducible results across experimental batches and research sites.

Research Summary

PT-141 represents a valuable research tool for investigating MC3R and MC4R receptor pharmacology through its selective binding profile and robust functional responses in recombinant cell systems. The compound's well-characterised binding kinetics, signalling pathway activation, and receptor subtype selectivity make it suitable for structure-activity relationship studies and mechanistic investigations of melanocortin receptor biology in controlled laboratory environments.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.